Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33

Reviewer: John P. Plastaras, MD, PhD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 16 de diciembre del 2006

Translation for this article does not exist


Where Are the Adults in the Room?
by Rodney Warner, JD
November 20, 2015